MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

MDT

88.96

+0.59%↑

VEEV

226.47

-0.52%↓

A

115.98

+2.05%↑

HQY

88.73

+1.89%↑

PDCO

31.27

+0.06%↑

Search

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

151.77 0.93

Overview

Share price change

24h

Current

Min

148.84

Max

154.83

Key metrics

By Trading Economics

Income

61M

-38M

Sales

116M

174M

EPS

-0.64

Profit margin

-22.119

Employees

1,017

EBITDA

33M

-38M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+37.9% upside

Dividends

By Dow Jones

Next Earnings

1 May 2025

Market Stats

By TradingEconomics

Market Cap

9.4B

Previous open

150.84

Previous close

151.77

News Sentiment

By Acuity

50%

50%

180 / 386 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Ascendis Pharma A-S ADR Chart

Past performance is not a reliable indicator of future results.

Related News

12 Aug 2024, 13:03 UTC

Major Market Movers

Ascendis Pharma Shares Climb on U.S. FDA Approval for Hypoparathyroidism Treatment Yorvipath

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

37.9% upside

12 Months Forecast

Average 208.82 USD  37.9%

High 289 USD

Low 162 USD

Based on 12 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

12 ratings

11

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

143.81 / 161.01Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

180 / 386 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.